Source: Annual Congress 2006 - Pro/Con: asthma is (not) an inflammatory disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Bousquet (Montpellier, France). Give me the patient's smooth muscle cells and I will tell you how to develop effective anti-asthma therapy – Con. Annual Congress 2006 - Pro/Con: asthma is (not) an inflammatory disease

Member's Comments

No comment yet.

Related content which might interest you: Give me the patient's smooth muscle cells and I will tell you how to develop effective anti-asthma therapy – Pro Source: Annual Congress 2006 - Pro/Con: asthma is (not) an inflammatory disease Year: 2006 Treating smooth muscle medically: anti-TNF treatment Source: Annual Congress 2007 - Novel therapies for severe asthma Year: 2007 Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy Source: Eur Respir Rev 2008; 17: 41-42 Year: 2008 Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy Source: Eur Respir J 2007; 30: Suppl. 51, 713s Year: 2007 What can we learn about airway smooth muscle from the company it keeps? Source: Eur Respir J 2008; 32: 9-11 Year: 2008 Beta2-agonists but not glucocorticoids inhibit proliferation of asthmatic airway smooth muscle cells Source: Eur Respir J 2004; 24: Suppl. 48, 251s Year: 2004 Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations Source: Eur Respir J 2004; 24 : 659-663 Year: 2004 Predicting physician decision to prescribe systemic corticosteroids following an exacerbation of airways disease Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 The way to improve the steroid sensitivity of target cells of patients with severe therapy resistant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 313s Year: 2006 How effective are oral steroids in asthma action plans? Source: International Congress 2017 – Asthma management Year: 2017 Do we need new therapies for noneosinophilic asthma? Source: Annual Congress 2004 - Noneosinophilic asthma Year: 2004 Ciclosporin as a steroid sparing agent in children with difficult to treat asthma Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Corticosteroids and beta2-agonists modify hyaluronic acid homeostasis in human airway smooth muscle cells in asthma and COPD Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009 Relative corticosteroid insensitivity in human airway smooth muscle cells from severe asthma patients in terms of transrepression not transactivation Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010 Treating asthma means treating airway smooth muscle cells Source: Eur Respir J 2008; 32: 265-274 Year: 2008 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Cell therapy by adipose stromal cells affect tracheal responsiveness and inflammatory responses in guinea pigs model of COPD Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Corticosteroids and beta2-agonists regulate pathologic homeostasis of hyaluronic acid in human airway smooth muscle cells from patients with asthma and COPD. Therapeutic relevance Source: Annual Congress 2010 - Airway cells as targets for anti-inflammatory drugs Year: 2010 Corticosteroid insensitivity in airway smooth muscle cells of severe asthma and COPD: Modulation by IFN-γ Source: Annual Congress 2012 - Basic and translational studies in COPD Year: 2012 Does combination therapy lead to better adherence in asthma? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010